Item 1.02 Termination of a Material Definitive Agreement. On September 9, 2026, Indivior UK Limited ("Indivior") and Reckitt Benckiser Healthcare (UK) Limited ("RB") entered into a Deed of Variation and Termination relating to that certain Copacker Supply Agreement dated December 23, 2014, as was amended on March 29, 2019 (the "Copacker Supply Agreement").…
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together - with science, people living with OUD, public health champions, and communities - we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.02Item 1.02 - Termination of Material Agreement
Item 1.02 Termination of a Material Definitive Agreement.
On September 9, 2026, Indivior UK Limited ("Indivior") and Reckitt Benckiser Healthcare (UK) Limited ("RB") entered into a Deed of Variation and Termination relating to that certain Copacker Supply Agreement dated December 23, 2014, as was amended on March 29, 2019 (the "Copacker Supply Agreement"). RB manufactures SUBOXONE® Tablets and SUBUTEX® Tablets for Indivior pursuant to the terms of the Copacker Supply Agreement. Pursuant to the Deed of Variation and Termination, the parties agreed to accelerate the termination date of the Copacker Supply Agreement to January 15, 2027. The Copacker Supply Agreement, as amended by the Deed of Variation and Termination, will remain in effect until the accelerated termination date. Indivior has identified a new supplier. Indivior's obligations under its agreement with its new supplier will become enforceable against it only after validation of the new supplier's manufacturing process, and this agreement is not expected to be material to Indivior Pharmaceuticals, Inc. (the “Registrant”).
Pursuant to the Deed of Variation and Termination, (i) RB has agreed to manufacture additional units prior to the new termination date, and (ii) Indivior has agreed to pay certain costs to RB including costs resulting from Indivior ordering lower volumes from RB than contemplated by the Copacker Supply Agreement, certain asset disposal and depreciation recovery costs, certain redundancy costs, certain incentive costs, and potential third party costs. The aggregate amount of such costs are fixed or capped and will not be material to the Registrant.
The foregoing description of the Deed of Variation and Termination is qualified in its entirety by reference to the full text of the Deed of Variation and Termination which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
